Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study
- PMID: 38003983
- PMCID: PMC10673463
- DOI: 10.3390/medicina59111935
Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study
Abstract
Background and Objectives: Inflammatory bowel disease (IBD) is a condition characterized by chronic intestinal inflammation. We can identify two major forms: Crohn's disease (CD) and ulcerative colitis (UC). One of the extraintestinal manifestations of IBD is nonalcoholic fatty liver disease (NAFLD). IBD and NAFLD share common pathogenetic mechanisms. Ultrasound (US) examination is the most commonly used imaging method for the diagnosis of NAFLD. This cross-sectional observational retrospective study aimed to evaluate the US prevalence of NAFLD in IBD patients and their clinical features. Materials and Methods: A total of 143 patients with IBD underwent hepatic US and were divided into two different groups according to the presence or absence of NAFLD. Subsequently, new exclusion criteria for dysmetabolic comorbidities (defined as plus) were applied. Results: The US prevalence of NAFLD was 23% (21% in CD and 24% in UC, respectively). Most IBD-NAFLD patients were male and older and showed significantly higher values for body mass index, waist circumference, disease duration, and age at onset than those without NAFLD. IBD-NAFLD patients showed a significantly higher percentage of stenosing phenotype and left-side colitis. Regarding metabolic features, IBD-NAFLD patients showed a significantly higher percentage of hypertension and IBD plus dysmetabolic criteria. Also, higher values of alanine aminotransferase and triglycerides and lower levels of high-density lipoproteins are reported in these patients. Conclusions: We suggest performing liver US screening in subjects affected by IBD to detect NAFLD earlier. Also, patients with NAFLD present several metabolic comorbidities that would fall within the new definition of metabolic-associated fatty liver disease. Finally, we encourage larger longitudinal studies, including healthy controls, to provide further confirmation of our preliminary data.
Keywords: Crohn’s disease; hepatic ultrasound; liver steatosis; metabolism; ulcerative colitis.
Conflict of interest statement
Ludovico Abenavoli is the Guest editor of the Special Issue “Editorial Board Members’ Collection Series: Gastrointestinal and Hepatic Diseases”.
Figures
Similar articles
-
Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history.World J Gastroenterol. 2019 Oct 7;25(37):5676-5686. doi: 10.3748/wjg.v25.i37.5676. World J Gastroenterol. 2019. PMID: 31602167 Free PMC article.
-
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.J Crohns Colitis. 2013 Sep;7(8):e279-85. doi: 10.1016/j.crohns.2012.10.015. Epub 2012 Nov 15. J Crohns Colitis. 2013. PMID: 23158500
-
Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients.Dig Dis Sci. 2017 May;62(5):1354-1361. doi: 10.1007/s10620-017-4495-0. Epub 2017 Mar 6. Dig Dis Sci. 2017. PMID: 28265826
-
Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together.Int J Mol Sci. 2024 Mar 14;25(6):3278. doi: 10.3390/ijms25063278. Int J Mol Sci. 2024. PMID: 38542249 Free PMC article. Review.
-
Systematic Review With Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease.Inflamm Bowel Dis. 2019 Oct 18;25(11):1764-1772. doi: 10.1093/ibd/izz043. Inflamm Bowel Dis. 2019. PMID: 30918952
Cited by
-
Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients.BMC Gastroenterol. 2024 Feb 23;24(1):81. doi: 10.1186/s12876-024-03160-8. BMC Gastroenterol. 2024. PMID: 38395765 Free PMC article.
-
The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation.Medicina (Kaunas). 2024 Mar 29;60(4):563. doi: 10.3390/medicina60040563. Medicina (Kaunas). 2024. PMID: 38674209 Free PMC article. Review.
-
Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study.Life (Basel). 2024 Sep 25;14(10):1226. doi: 10.3390/life14101226. Life (Basel). 2024. PMID: 39459526 Free PMC article.
-
Editorial Board Members' Collection Series: Gastrointestinal and Hepatic Diseases.Medicina (Kaunas). 2025 Apr 20;61(4):758. doi: 10.3390/medicina61040758. Medicina (Kaunas). 2025. PMID: 40283049 Free PMC article.
-
Association between different obesity patterns and the risk of NAFLD detected by transient elastography: a cross-sectional study.BMC Gastroenterol. 2024 Jul 10;24(1):221. doi: 10.1186/s12876-024-03303-x. BMC Gastroenterol. 2024. PMID: 38987694 Free PMC article.
References
-
- Spagnuolo R., Larussa T., Iannelli C., Cosco C., Nisticò E., Manduci E., Bruno A., Boccuto L., Abenavoli L., Luzza F., et al. COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey. Medicina. 2020;56:407. doi: 10.3390/medicina56080407. - DOI - PMC - PubMed
-
- Malik T.F., Aurelio D.M. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2023. Extraintestinal Manifestations of Inflammatory Bowel Disease. - PubMed
-
- Martínez-Domínguez S.J., García-Mateo S., Laredo V., Gargallo-Puyuelo C.J., Gallego Llera B., López de la Cruz J., Gomollón F. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review. Cancers. 2023;15:3367. doi: 10.3390/cancers15133367. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical